Etanercept overview of clinical experience in the treatment of psoriasis and psoriatic arthritis
Biologics have revolutionized the management of psoriasis and psoriatic arthritis. Etanercept was the first biologic to be approved in Europe for the treatment of psoriatic arthritis in 2002 and since 2005 has been approved for the treatment of psoriasis as well. This provides approximately 8 years...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical rheumatology 2011-04, Vol.6 (2), p.135-155 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 155 |
|---|---|
| container_issue | 2 |
| container_start_page | 135 |
| container_title | International journal of clinical rheumatology |
| container_volume | 6 |
| creator | Bachmann, Frank Kokolakis, Georgios Sterry, Wolfram Philipp, Sandra |
| description | Biologics have revolutionized the management of psoriasis and psoriatic arthritis. Etanercept was the first biologic to be approved in Europe for the treatment of psoriatic arthritis in 2002 and since 2005 has been approved for the treatment of psoriasis as well. This provides approximately 8 years of experience in the treatment of psoriasis, nearly a decade, which prompted us to review the available data with a special focus on dermatology and compare it with other existing treatment modalities. The aim of this article is to give an update on etanercept with emphasis on information that is important for practical daily use. Most data are based on high-quality studies and official guidelines but, if necessary, data from recent publications or clinical expertise have also been added. |
| doi_str_mv | 10.2217/ijr.10.104 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_870525038</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A254112867</galeid><sourcerecordid>A254112867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c287t-4751ef7fa116c09f8853741bfc7c4d159719f0f125fc519537b3b772e6690a9a3</originalsourceid><addsrcrecordid>eNptkUtPAyEUhSdGExt14y8gujNpBWYYmGXT1Edi4kbXSOnF3qbDjEB9_Hup05iYyF1wLnwHknuK4pzRCedMXuM6TLJmtDooRkwKNa64ooe_WvLj4izGNc2rZJVq6Kh4mSfjIVjoE-neIbwjfJDOEbtBj9ZsCHz2EBC8BYKepBWQFMCkFnzacX3sApqIkRi_3HcJLTEhrQImjKfFkTObCGf7_aR4vpk_ze7GD4-397Ppw9hyJdO4koKBk84wVlvaOKVEKSu2cFbaaslEI1njqGNcOCtYky8X5UJKDnXdUNOY8qS4GN7tQ_e2hZj0utsGn7_USlLBBS1Vhi4H6NVsQKN3XQrGthitnnJRMcZVLTM1-YfKtYQWbefBYT7_Y7gaDDZ0MQZwug_YmvClGdW7aHSOZqdzNBmuB9ht0zZAtD_D1UPXwhItevjP-A3wSJMu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>870525038</pqid></control><display><type>article</type><title>Etanercept overview of clinical experience in the treatment of psoriasis and psoriatic arthritis</title><source>Alma/SFX Local Collection</source><creator>Bachmann, Frank ; Kokolakis, Georgios ; Sterry, Wolfram ; Philipp, Sandra</creator><creatorcontrib>Bachmann, Frank ; Kokolakis, Georgios ; Sterry, Wolfram ; Philipp, Sandra</creatorcontrib><description>Biologics have revolutionized the management of psoriasis and psoriatic arthritis. Etanercept was the first biologic to be approved in Europe for the treatment of psoriatic arthritis in 2002 and since 2005 has been approved for the treatment of psoriasis as well. This provides approximately 8 years of experience in the treatment of psoriasis, nearly a decade, which prompted us to review the available data with a special focus on dermatology and compare it with other existing treatment modalities. The aim of this article is to give an update on etanercept with emphasis on information that is important for practical daily use. Most data are based on high-quality studies and official guidelines but, if necessary, data from recent publications or clinical expertise have also been added.</description><identifier>ISSN: 1758-4272</identifier><identifier>EISSN: 1758-4280</identifier><identifier>DOI: 10.2217/ijr.10.104</identifier><language>eng</language><publisher>London: Future Medicine Ltd</publisher><subject>Antirheumatic agents ; biologics ; dermatology ; Drug therapy ; Etanercept ; fusion protein ; Pharmaceutical industry ; psoriasis ; Psoriatic arthritis ; safety ; therapeutic use ; therapy ; TNF inhibitor ; TNF-αα ; Tumors</subject><ispartof>International journal of clinical rheumatology, 2011-04, Vol.6 (2), p.135-155</ispartof><rights>COPYRIGHT 2011 Future Medicine Ltd.</rights><rights>2011 © Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c287t-4751ef7fa116c09f8853741bfc7c4d159719f0f125fc519537b3b772e6690a9a3</citedby><cites>FETCH-LOGICAL-c287t-4751ef7fa116c09f8853741bfc7c4d159719f0f125fc519537b3b772e6690a9a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Bachmann, Frank</creatorcontrib><creatorcontrib>Kokolakis, Georgios</creatorcontrib><creatorcontrib>Sterry, Wolfram</creatorcontrib><creatorcontrib>Philipp, Sandra</creatorcontrib><title>Etanercept overview of clinical experience in the treatment of psoriasis and psoriatic arthritis</title><title>International journal of clinical rheumatology</title><description>Biologics have revolutionized the management of psoriasis and psoriatic arthritis. Etanercept was the first biologic to be approved in Europe for the treatment of psoriatic arthritis in 2002 and since 2005 has been approved for the treatment of psoriasis as well. This provides approximately 8 years of experience in the treatment of psoriasis, nearly a decade, which prompted us to review the available data with a special focus on dermatology and compare it with other existing treatment modalities. The aim of this article is to give an update on etanercept with emphasis on information that is important for practical daily use. Most data are based on high-quality studies and official guidelines but, if necessary, data from recent publications or clinical expertise have also been added.</description><subject>Antirheumatic agents</subject><subject>biologics</subject><subject>dermatology</subject><subject>Drug therapy</subject><subject>Etanercept</subject><subject>fusion protein</subject><subject>Pharmaceutical industry</subject><subject>psoriasis</subject><subject>Psoriatic arthritis</subject><subject>safety</subject><subject>therapeutic use</subject><subject>therapy</subject><subject>TNF inhibitor</subject><subject>TNF-αα</subject><subject>Tumors</subject><issn>1758-4272</issn><issn>1758-4280</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkUtPAyEUhSdGExt14y8gujNpBWYYmGXT1Edi4kbXSOnF3qbDjEB9_Hup05iYyF1wLnwHknuK4pzRCedMXuM6TLJmtDooRkwKNa64ooe_WvLj4izGNc2rZJVq6Kh4mSfjIVjoE-neIbwjfJDOEbtBj9ZsCHz2EBC8BYKepBWQFMCkFnzacX3sApqIkRi_3HcJLTEhrQImjKfFkTObCGf7_aR4vpk_ze7GD4-397Ppw9hyJdO4koKBk84wVlvaOKVEKSu2cFbaaslEI1njqGNcOCtYky8X5UJKDnXdUNOY8qS4GN7tQ_e2hZj0utsGn7_USlLBBS1Vhi4H6NVsQKN3XQrGthitnnJRMcZVLTM1-YfKtYQWbefBYT7_Y7gaDDZ0MQZwug_YmvClGdW7aHSOZqdzNBmuB9ht0zZAtD_D1UPXwhItevjP-A3wSJMu</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Bachmann, Frank</creator><creator>Kokolakis, Georgios</creator><creator>Sterry, Wolfram</creator><creator>Philipp, Sandra</creator><general>Future Medicine Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20110401</creationdate><title>Etanercept overview of clinical experience in the treatment of psoriasis and psoriatic arthritis</title><author>Bachmann, Frank ; Kokolakis, Georgios ; Sterry, Wolfram ; Philipp, Sandra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c287t-4751ef7fa116c09f8853741bfc7c4d159719f0f125fc519537b3b772e6690a9a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antirheumatic agents</topic><topic>biologics</topic><topic>dermatology</topic><topic>Drug therapy</topic><topic>Etanercept</topic><topic>fusion protein</topic><topic>Pharmaceutical industry</topic><topic>psoriasis</topic><topic>Psoriatic arthritis</topic><topic>safety</topic><topic>therapeutic use</topic><topic>therapy</topic><topic>TNF inhibitor</topic><topic>TNF-αα</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bachmann, Frank</creatorcontrib><creatorcontrib>Kokolakis, Georgios</creatorcontrib><creatorcontrib>Sterry, Wolfram</creatorcontrib><creatorcontrib>Philipp, Sandra</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bachmann, Frank</au><au>Kokolakis, Georgios</au><au>Sterry, Wolfram</au><au>Philipp, Sandra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Etanercept overview of clinical experience in the treatment of psoriasis and psoriatic arthritis</atitle><jtitle>International journal of clinical rheumatology</jtitle><date>2011-04-01</date><risdate>2011</risdate><volume>6</volume><issue>2</issue><spage>135</spage><epage>155</epage><pages>135-155</pages><issn>1758-4272</issn><eissn>1758-4280</eissn><abstract>Biologics have revolutionized the management of psoriasis and psoriatic arthritis. Etanercept was the first biologic to be approved in Europe for the treatment of psoriatic arthritis in 2002 and since 2005 has been approved for the treatment of psoriasis as well. This provides approximately 8 years of experience in the treatment of psoriasis, nearly a decade, which prompted us to review the available data with a special focus on dermatology and compare it with other existing treatment modalities. The aim of this article is to give an update on etanercept with emphasis on information that is important for practical daily use. Most data are based on high-quality studies and official guidelines but, if necessary, data from recent publications or clinical expertise have also been added.</abstract><cop>London</cop><pub>Future Medicine Ltd</pub><doi>10.2217/ijr.10.104</doi><tpages>21</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1758-4272 |
| ispartof | International journal of clinical rheumatology, 2011-04, Vol.6 (2), p.135-155 |
| issn | 1758-4272 1758-4280 |
| language | eng |
| recordid | cdi_proquest_journals_870525038 |
| source | Alma/SFX Local Collection |
| subjects | Antirheumatic agents biologics dermatology Drug therapy Etanercept fusion protein Pharmaceutical industry psoriasis Psoriatic arthritis safety therapeutic use therapy TNF inhibitor TNF-αα Tumors |
| title | Etanercept overview of clinical experience in the treatment of psoriasis and psoriatic arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A49%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Etanercept%20overview%20of%20clinical%20experience%20in%20the%20treatment%20of%20psoriasis%20and%20psoriatic%20arthritis&rft.jtitle=International%20journal%20of%20clinical%20rheumatology&rft.au=Bachmann,%20Frank&rft.date=2011-04-01&rft.volume=6&rft.issue=2&rft.spage=135&rft.epage=155&rft.pages=135-155&rft.issn=1758-4272&rft.eissn=1758-4280&rft_id=info:doi/10.2217/ijr.10.104&rft_dat=%3Cgale_proqu%3EA254112867%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=870525038&rft_id=info:pmid/&rft_galeid=A254112867&rfr_iscdi=true |